Occurence of Pain and Use of Analgesic Treatment in Multi-trauma Patients of Intermediate Seveity

Overview

To register the perceived pain score during 0-14 days after multitrauma in conscious patients and to register the use (type and dose) of analgesic treatment in the same period.

Full Title of Study: “The Incidence and Strenght of Pain in Conscious Multitrauma Patients, 0-14 Days After Multitrauma”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2019

Interventions

  • Drug: analgesic drugs and methods
    • the patient will receive analgesic treatment at the discretion of the physician in charge

Clinical Trial Outcome Measures

Primary Measures

  • Worst pain
    • Time Frame: 0-14 days
    • NRS scale, 0-10
  • Average pain
    • Time Frame: 0-14 days
    • NRS scale, 0-10

Secondary Measures

  • analgesic methods
    • Time Frame: 0-14 days
    • list of drugs (dose and duration) and other analgesic measures

Participating in This Clinical Trial

Inclusion Criteria

  • Patient With trauma, ISS > 8 Exclusion Criteria:

  • Unconscious patients at admission – patients due for major surgery within 3 hrs of admission – patients primary admitted to other hospitals – not able to communicate in Norewegian

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Investigator Details

  • Lead Sponsor
    • Oslo University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Johan C Ræder, professor – Oslo University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.